Search Orphan Drug Designations and Approvals
-
| Generic Name: | Mitoxantrone HCl | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Novantrone | ||||||||||||||||
| Date Designated: | 07/13/1987 | ||||||||||||||||
| Orphan Designation: | Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia. | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Lederle Laboratories Division of American Cyanamid Company 401 N. Middletown Road Pearl River, New York 10965 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | Mitoxantrone HCl |
|---|---|---|
| Trade Name: | Novantrone | |
| Marketing Approval Date: | 12/23/1987 | |
| Approved Labeled Indication: | ||
| Exclusivity End Date: | 12/23/1994 | |
| Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







